(Q36873029)

16 August 2017

1 reference

title

Pregabalin: an antiepileptic agent useful for neuropathic pain (English)

1 reference

16 August 2017

0 references

Matthew L Blommel

1

1 reference

PubMed ID

17617497

16 August 2017

Amy L Blommel

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

American Journal of Health-System Pharmacy

16 August 2017

1 reference

16 August 2017

64

1 reference

16 August 2017

14

1 reference

16 August 2017

1475-1482

1 reference

Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy

16 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

The management of post-herpetic neuralgia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin: a new agent for the treatment of neuropathic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Defining success in clinical trials--profiling pregabalin, the newest AED.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin: in the treatment of postherpetic neuralgia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

3-substituted GABA analogs with central nervous system activity: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

Pregabalin: in the treatment of painful diabetic peripheral neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060371

31 March 2020

Identifiers

DOI

10.2146/AJHP060371

1 reference

16 August 2017

1 reference

PubMed ID

17617497